These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2675183)

  • 1. Bone and soft-tissue lesions: diagnosis with combined H-1 MR imaging and P-31 MR spectroscopy.
    Negendank WG; Crowley MG; Ryan JR; Keller NA; Evelhoch JL
    Radiology; 1989 Oct; 173(1):181-8. PubMed ID: 2675183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes of 3-tesla 31P-MR spectroscopy of bone and soft tissue tumors].
    Qi ZH; Li CF; Ma XX; Li ZF; Zhang K; Yu DX
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):442-6. PubMed ID: 19950555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [31P-MR spectroscopy of bone and soft tissue lesions].
    Kitagawa A; Saeki M; Imamura K; Ohashi K; Ishikawa T; Nakajima H; Takagi M
    Nihon Igaku Hoshasen Gakkai Zasshi; 1995 Dec; 55(15):1017-24. PubMed ID: 8587841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: initial results.
    Wang CK; Li CW; Hsieh TJ; Chien SH; Liu GC; Tsai KB
    Radiology; 2004 Aug; 232(2):599-605. PubMed ID: 15286325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary study of 3T 1H MR spectroscopy in bone and soft tissue tumors.
    Qi ZH; Li CF; Li ZF; Zhang K; Wang Q; Yu DX
    Chin Med J (Engl); 2009 Jan; 122(1):39-43. PubMed ID: 19187615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MR imaging of soft-tissue masses: diagnostic efficacy and value of distinguishing between benign and malignant lesions.
    Moulton JS; Blebea JS; Dunco DM; Braley SE; Bisset GS; Emery KH
    AJR Am J Roentgenol; 1995 May; 164(5):1191-9. PubMed ID: 7717231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined MR imaging and spectroscopy of bone and soft tissue tumors.
    Zlatkin MB; Lenkinski RE; Shinkwin M; Schmidt RG; Daly JM; Holland GA; Frank T; Kressel HY
    J Comput Assist Tomogr; 1990; 14(1):1-10. PubMed ID: 2153717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benign and malignant musculoskeletal lesions: dynamic contrast-enhanced MR imaging--parametric "first-pass" images depict tissue vascularization and perfusion.
    Verstraete KL; De Deene Y; Roels H; Dierick A; Uyttendaele D; Kunnen M
    Radiology; 1994 Sep; 192(3):835-43. PubMed ID: 8058957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study.
    Bartella L; Morris EA; Dershaw DD; Liberman L; Thakur SB; Moskowitz C; Guido J; Huang W
    Radiology; 2006 Jun; 239(3):686-92. PubMed ID: 16603660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osseous invasion by soft-tissue sarcoma: assessment with MR imaging.
    Elias DA; White LM; Simpson DJ; Kandel RA; Tomlinson G; Bell RS; Wunder JS
    Radiology; 2003 Oct; 229(1):145-52. PubMed ID: 14519874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benign and malignant masses. MR imaging differentiation.
    Weatherall PT
    Magn Reson Imaging Clin N Am; 1995 Nov; 3(4):669-94. PubMed ID: 8564689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soft-tissue tumors: value of static and dynamic gadopentetate dimeglumine-enhanced MR imaging in prediction of malignancy.
    van Rijswijk CS; Geirnaerdt MJ; Hogendoorn PC; Taminiau AH; van Coevorden F; Zwinderman AH; Pope TL; Bloem JL
    Radiology; 2004 Nov; 233(2):493-502. PubMed ID: 15459325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of musculoskeletal lesions on 3-T proton MR spectroscopy.
    Fayad LM; Barker PB; Jacobs MA; Eng J; Weber KL; Kulesza P; Bluemke DA
    AJR Am J Roentgenol; 2007 Jun; 188(6):1513-20. PubMed ID: 17515370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of early imaging response after chemoembolization of hepatocellular carcinoma by phosphorus-31 magnetic resonance spectroscopy-initial experience.
    Yuan Z; Ye XD; Dong S; Xu LC; Xiao XS
    J Vasc Interv Radiol; 2011 Aug; 22(8):1166-73. PubMed ID: 21703872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 31-P mr spectroscopy of a leg lymphangiosarcoma.
    Kiricuta IC; Bluemm RG; Krawzak HW; Rühl J; Beyer HK
    Lymphology; 1994 Jun; 27(2):82-9. PubMed ID: 8078364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary study of proton magnetic resonance spectroscopy in bone and soft tissue tumors: an unassigned signal at 2.0-2.1 ppm may be a possible indicator of malignant neuroectodermal tumor.
    Oya N; Aoki J; Shinozaki T; Watanabe H; Takagishi K; Endo K
    Radiat Med; 2000; 18(3):193-8. PubMed ID: 10972550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soft-tissue sarcomas: MR imaging and MR spectroscopy for prognosis and therapy monitoring. Work in progress.
    Dewhirst MW; Sostman HD; Leopold KA; Charles HC; Moore D; Burn RA; Tucker JA; Harrelson JM; Oleson JR
    Radiology; 1990 Mar; 174(3 Pt 1):847-53. PubMed ID: 2154837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic resonance angiography without contrast enhancement medium in bone and soft tissue tumors.
    Doi H; Ono A; Kawai A; Morimoto Y; Kunisada T; Nakata E; Ozaki T
    Oncol Rep; 2006 Mar; 15(3):681-5. PubMed ID: 16465430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary musculoskeletal tumors: examination with MR imaging compared with conventional modalities.
    Pettersson H; Gillespy T; Hamlin DJ; Enneking WF; Springfield DS; Andrew ER; Spanier S; Slone R
    Radiology; 1987 Jul; 164(1):237-41. PubMed ID: 3588912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of MRS in the differentiation of benign and malignant soft tissue and bone tumors.
    Doganay S; Altinok T; Alkan A; Kahraman B; Karakas HM
    Eur J Radiol; 2011 Aug; 79(2):e33-7. PubMed ID: 21376496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.